Answers are grounded in this paper and cite their sources.
The review of the literature presents the basic information on the use of intravenous immunoglobulins (IVIg) in pediatric hematology-oncology and in the context of hematopoietic stem cell transplantation in the historical perspective and at the present stage. The main requirements for IVIg are shown, which consist in the use of safe and quality solutions with a high content of immunoglobulins, which bear minimal risks for patients. The author presents the main indications, which include pathogenetic therapy of autoimmune and viral diseases (complications) and substitution therapy for the purpose of correction of secondary immunodeficiency against chemotherapy and targeted therapy.
No takes yet. Share an insight, caveat, or question.
K. I. Kirgizov (2018) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: